Javelin Biotech’s Post

“Fictiv enabled us to save millions of dollars in infrastructure, people and time costs when compared to traditional development and supply chain strategies.” - Gene Vetter, Co-Founder & CEO of TransMed7. In this recent case study, discover how a medical device company used Fictiv to shorten development cycles from weeks to days, and production manufacturing from months to weeks. Ultimately, Fictiv helped accelerate NPI from 10 to 2 years for five new breakthrough medical devices. Learn more: https://hubs.ly/Q02R3WH10 – #MedDeviceUS24 #GenerisAMD #Fictiv #globalsupplychain #digitalmanufacturing #custommanufacturing

🤩 Excited for the upcoming Advances in Cell-Based Screening for Drug Discovery conference in Gothenburg this week! Can't wait to connect with fellow attendees. 🤝 If you're going to be there and would like to catch up, feel free to reach out. You can also locate me by my poster (#51) with the title "DEVELOPMENT OF A NEW AFFINITY RANKING METHOD USING LIGANDTRACER TECHNOLOGY IN REAL-TIME ON LIVE CELLS". 📜 #LigandTracer #DiscoverMolecularInteractions  #realtimebindinginteractions #drugdesign 

Enterprise collaboration is quite important in accelerating drug development. check out this one !!!

Thrilled to share our #RSCPoster: "Dual Stimuli-Responsive NanoSensoGel Formulation Technology to Prevent Chemotherapeutic-Induced Ototoxicity"! 🎉 This work explores the development of a dual stimuli-responsive NanoSensoGel, harnessing innovative chemistry for targeted inner ear drug delivery. 🔬 Through rational molecular design, we've engineered nanogel components that respond to ROS and temperature, enabling sustained and localized drug release. 🌡️ Our cell studies demonstrate efficient cellular uptake, triggered drug release, and remarkable ototoxicity protection. 🔥 This highlights the power of chemistry in driving design innovations, optimizing drug delivery, and preventing hearing loss induced by chemotherapy. 👂 Check out full publication in #JournalofControlledRelease (https://lnkd.in/dZgndqbj). The team: @Iulia Rus, Ethan Sparks, and Dr. Vibhuti Agrahari  Stay tuned for more exciting updates on this pioneering research! #RSCNano #NanoTechnology #OtologicalResearch #ChemistryMatters #drugdelivery #hearingloss #formulationdevelopment #designofexperiments #rscposter

Multiomics research applications using single-cell analysis are driving precision medicine research forward. Take a look at our single-cell multiomics roadmap with Ranga Partha, VP of global marketing and strategic growth areas, and Aruna S. Ayer, PhD., senior director of R&D, single cell & advanced technologies. The two of them sat down with GenomeWeb for an exclusive interview to talk about recent and upcoming new products for multiomics research designed for use on the BD Rhapsody™ Single-Cell Analysis System. #singlecell #BD #multiomics #precisionmedicine #BD Rhapsody #BDInnovation #BDBiosciences

📣 NEW CAR-T Data ‼️ Join David Smith on 2/29 at the CAR-TCR Summit Series Europe for the presentation of the first public CAR-T expansion data from BioCentriq’s collaboration with Terumo Blood and Cell Technologies. The data will demonstrate for the first time publicly, the ability to rapidly produce CAR-T cells using protocols developed by Terumo BCT for its Quantum Flex and Finia® Fill and Finish System platforms in tandem with BioCentriq’s LEAP™ Advanced Therapy Platform. “This collaboration takes aim at the manufacturing bottlenecks that have adversely impacted patient access to CAR-T’s and other advanced therapies,” said David Smith, Ph.D., Vice President of Development at BioCentriq. “It demonstrates how BioCentriq is leveraging Terumo BCT’s platforms to shorten manufacturing timelines and accelerate the development of new therapies.” #CARTCR24 #advancedtherapies #cartcelltherapy #CART #celltherapy #biocentriq #terumo #collaboration #HOPE

David Smith, Vice President of Development at BioCentriq, emphasized the crucial role of CAR-T cells in the collaboration aimed at tackling manufacturing bottlenecks. CAR-T therapies represent a cutting-edge approach in the realm of personalized medicine, offering promising avenues for treating various diseases, particularly cancer. However, the complexities associated with manufacturing CAR-T cells have posed significant challenges, impacting patient access to these innovative treatments. Through the partnership with Terumo Blood and Cell Technologies, BioCentriq is strategically leveraging advanced platforms to address these hurdles. By optimizing manufacturing processes specifically tailored for CAR-T cells, BioCentriq aims to enhance efficiency, scalability, and reliability in producing these transformative therapies. This collaboration underscores BioCentriq's dedication to advancing CAR-T cell therapy by overcoming manufacturing barriers, ultimately ensuring broader patient access and accelerating the development of next-generation treatments. CAR-TCR Summit Series #immunotherapy #cartcelltherapy #cartcrsummitseries #cancerresearch #cancertreatment #tcrtherapy #innovation

DNA-encoded library (DEL) technology accelerates #drugdiscovery by using vast libraries of tiny #molecules, each tagged with #DNA for rapid identification and sorting. Enhanced with dynamic libraries, a path-coding algorithm, binding profiler validation, and MicroMapping for precise #spatialanalysis, this approach streamlines the search for new medicines. Learn more in this on-demand webinar.

Small Molecule CDMO's - What matters today? As I wrap up a week of meetings in the Bay Area on behalf of AustinPx, I thought I would share my takeaways. I come from a novel methods and instrumentation background, so it has been interesting to see and hear what matters today as companies evaluate a #smallmolecule CDMO. AustinPx is unique in that they have most of the standard #cdmo offerings, but they also have Kinetisol....a CDMO+ if you will. I always gravitate to the new and exciting, and for the most part, the researchers we spoke with did the same. Kinetisol is no doubt a game changer for many molecules as it renders molecules #amorphous without the need for solvent (like spray drying) or heat input (like HME). It has a design space that far exceeds comparable methods for creating an amorphous dispersion. But what was even more interesting to me was that many clients are still looking for a consultative partner, even for the standard services. Lead times, expertise and responsiveness are all still front and center when it comes to choosing the right CDMO. I chose to consult with AustinPx because I trust their scientific team without question. They are exceptional. If you have a program, even if it is early in preclinical, it is worth having a conversation with Dave A. Miller, Ph.D. and his pharmaceutics team. Their approach to client projects balances the needs of the molecule with the realities of the program, and they will find the most efficient and effective scientific path forward. Exciting times to come. I am happy to be a small part of it!

🎶 It's summertime and the livin' is easy... 🎶 but fresh insights go with any weather, right? #TBT to Hamilton Bonaduz AG case study titled: “Enhancing Scalability and Quality of 3D In Vitro Cell Models Production through Automation” 🔔 This insightful resource describes the automated production and maintenance of spheroids via self-aggregation using our proprietary Akura™ microplate technology and Hamilton’s Microlab® STARlet. 👀 Read the Case Study and learn more about the: ✔️ Advantages of 3D in vitro cell models for drug discovery ✔️ Automation of the production of 3D in vitro cell models with the scalable Akura™ technology ✔️ Benefits of combining Akura™ technology and Hamilton’s pipetting technologies 👉 Link in comments Frauke Greve Gabriela Boza-Moran Carolina Elejalde Palmett Patrick Pfenninger Olivier Frey Lisa Hoelting Tamara Häfeli Agnieszka Pawlowska Ozlem Yavas Grining Judi Wardwell-Swanson Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Tina Žel Rositsa Hadzhipetrova #3dinvitromodels #liquidhandling #automation #scalability #drugdiscovery #TheModelofExcellence™